ComputerHunter.org

 

Orphan Drugs: Hope Where There Is Little or No Hope


NEW YORK, N.Y., February 18, 2004 ? On a visit to his doctor, Gary Jacob received distressing news ? not about himself, but a friend of the doctor's.

While playing with one of his children, the doctor's friend fell and broke a rib. That was bad enough, but during the examination at the hospital, the father was hit with a startling and totally unexpected diagnosis ? he had a disease known as multiple myeloma, a bone marrow blood cancer.

The diagnosis was nothing less than a death sentence.

Jacob knew of the anguish of multiple myeloma patients. The disease is incurable and nearly always fatal, one of the rare diseases that have few, if any, available treatments. They are known as "orphan" diseases, shunned by most drug-makers because the patient populations are small and commercial development of a drug is seen as economically unattractive.

Mr. Jacob was aware because, as Chief Executive Officer of Callisto Pharmaceuticals, Inc., a small Manhattan-based biopharmaceutical company, he is leading a scientific effort to develop a new orphan drug called "Atiprimod" for multiple myeloma patients.

"The father's disease brought home to me that what we are doing is really important," says Mr. Jacob. "Everyone agrees we need more drugs to treat multiple myeloma. There are people out there dying without real hope because of a lack of effective treatment for all patients."

In steadily increasing numbers, orphan drugs are providing new doses of hope where little or none at all existed. In the decade before the inception of the federal Food and Drug Administration's orphan drug program, 10 drugs were developed by pharmaceutical companies for orphan diseases. In the decades since, the FDA says nearly 250 new drugs were developed and approved, and hundreds more are in the pipeline.

Atiprimod is one of those wending its way toward the marketplace. Callisto recently obtained orphan drug designation from the FDA, providing the company with financial incentives to continue the costly development process.

The program covers drugs for orphan diseases with patient populations under 200,000.

The National Organization for Rare Disorders reports about 25 million people in the United States suffer from an estimated 6,000 orphan diseases.

Diseases such as cystic fibrosis, complications affecting HIV-infected people, Gaucher's disease, hemophilia and rare forms of cancer were among the orphans without effective medicines until the FDA program went into effect in 1983 and paved the way for new drugs for patients with these diseases.

Large drug-makers have been largely missing from the efforts.

According to the orphan drug program's deputy director, Dr. John McCormick, only 15% of applications for orphan drug designation have come from the larger pharmaceutical companies.

The reason: expectations of unfavorable investment returns.

The FDA orphan drug incentives ? grants, seven years of marketing exclusivity and tax breaks ? have drawn small pharmaceutical companies with promising drug candidates into the breach.

While the future is brighter, the task is still daunting to develop drugs for orphan diseases.

Amyotrophic lateral sclerosis (ALS), or Lou Gehrig's disease, affects 30,000 Americans with 8,000 new cases diagnosed annually; Huntington's disease also affects about 30,000 patients.

Some diseases affect fewer than 100 patients, according to the National Institutes of Health.

An estimated 50,000 patients have multiple myeloma with 15,000 new patients diagnosed each year. Last year, the FDA approved a new drug Velcade for patients with the disease. However, there are still a number of multiple myeloma patients with no treatment available.

Dr. Kenneth C. Anderson, who played a major role in the preclinical development and clinical trials of Velcade and is now a member of Callisto's Medical Advisory Board, is among the experts who see a need for more drugs to treat multiple myeloma.

"He is excited to see Atiprimod enter clinical trials for evaluation in multiple myeloma patients," Jacob said of Anderson. "He believes it has an opportunity to help patients who have not responded to other drugs. "

Dr. Anderson is director of the Jerome Lipper Multiple Myeloma Center of the Dana-Farber Cancer Institute in Boston, MA, and Professor of Medicine at Harvard Medical School.

The Phase I/IIa trials for Atiprimod are slated to begin later this month.

Dr. Donald Picker, Callisto's Senior Vice President of Drug Development, said studies of Atiprimod in collaboration with scientists at the National Cancer Institute have been very promising.

"In essence, we've shown in these early studies that Atiprimod has the potential to intervene with cancer cells and tumors in three ways ? by inhibiting their formation, by programming their death and by limiting their ability to grow blood vessels necessary for their survival. Taken together, these findings suggest that Atiprimod could potentially represent a novel class of compounds for development for therapeutic intervention in human cancers," said Dr. Picker.

About The Author

Alex Michelini is a former award-winning reporter/editor at the New York Daily News. His credits include nomination for a Pulitzer Prize for a series on medical costs. Among his honors, Mr. Michelini received the Deadline Club Award, the Page One Award, the Associated Press Award and the New York Press Club Award (twice). He is the founder of Alex Michelini Public Relations, and has developed and collaborated on articles appearing in the New York Times, the Wall Street Journal, the London Times, the New York Post, the New York Daily News, Bloomberg Radio & TV, CNNfn, WCBS Radio & TV. WINS radio, the Christian Science Monitor, Fox TV, Reuters, Newsday and other media outlets.

michelinialex@aol.com







Google News - Top Stories

USA Today

Debate day reading list for the second Obama/McCain verbal battle
Los Angeles Times - 1 hour ago
The second presidential debate is fast approaching. We'll be live blogging the Town-Hall style forum here, beginning at 5:30 pm PST, like we did the first faceoff between John McCain and Barack Obama and the encounter between the vice presidential ...
Nashville Knockout: What To Watch For Washington Post
Debate Round Two: It Just Might Get Nasty ABC News
Newsday - USA Today - New York Daily News - guardian.co.uk
all 1,623 news articles


ABC News

Dow dips more than 500 on worries about financials
Forbes - 3 hours ago
By TIM PARADIS 10.07.08, 5:16 PM ET The misery worsened on Wall Street Tuesday, with stocks piling on losses late in the session and bringing the two-day decline in the Dow Jones industrials to more than 875 points amid escalating worries about credit ...
Video: Stocks Fluctuate After Fed Corporate Debt Plan AssociatedPress
Dow plunges 508 points as Fed chief warns of dark days ahead guardian.co.uk
MarketWatch - TIME - ABC News - CNN
all 2,285 news articles


The Age

Two dead as Thai troops battle protesters
guardian.co.uk - 1 hour ago
Anti-government protesters clash with police outside the parliament in Bangkok. Photograph: Rungroj Yongrit/EPA Troops were deployed on the streets of Bangkok last night to bolster Thai police after a day of clashes with anti-government protesters left ...
Video: Raw Video: Tear Gas Fired at Thai Protestors AssociatedPress
Thai Army Sends Troops to Help Police Keep Peace Washington Post
Reuters - AFP - Bloomberg - The Associated Press
all 1,412 news articles


ABC News

Non-Profit Raided In Voter Fraud Probe
CBS News - 1 hour ago
ACORN workers Carlos McCoy and Charmaine Davis try to register voters Sept. 1, 2006, outside the Franklin County Courthouse in Columbus, Ohio.
ACORN office in Vegas raided in voter-fraud probe The Associated Press
ACORN Nevada Office Raided Washington Post
CNN Political Ticker - USA Today - Cleveland Leader - Nevada Appeal
all 185 news articles


Los Angeles Times

Reporter's Notebook: Star Witness Concludes Testimony in Stevens Trial
FOXNews - 2 hours ago
By Ian McCaleb The government's star witness in the trial of Alaska Sen. Ted Stevens left the court for good on Tuesday, having finished a draining new round of testimony, before the prosecution team rolled out more audio tapes it seems to think will ...
Stevens’s Lawyer Challenges Witness New York Times
On tape: Stevems' friends plotted to hide free work Minneapolis Star Tribune
Forbes - Washington Post - Los Angeles Times - United Press International
all 943 news articles

Google
 

Copyright © 2006 Computer Hunter - A Division of Arthur´s Job Base